



PRESS RELEASE

Revotar Biopharmaceuticals AG Receives 2.5 Million Euro Research Grant

Berlin/Hennigsdorf (Germany), September 15, 2009 - Revotar Biopharmaceuticals AG today announced that the company has been granted 2.5 million Euro from the German Federal State of Brandenburg for the development of its pipeline of selectin antagonists in respiratory indications.

The funding will be distributed over a 2-year period and is part of the European Regional Development Fund program. "We are very pleased that the State of Brandenburg has recognized the importance of our research," stated Dr. Martin Pöhlchen, CEO of Revotar. "We are also very encouraged by the professional support and the excellent scientific environment in Brandenburg and in Berlin."

"The funds will mainly be used to advance our preclinical and clinical programs of anti-inflammatory drugs for the treatment of chronic obstructive pulmonary disease (COPD)," added Prof. Wolfgang Meyer-Sabellek, Chief Medical Officer of Revotar. "Pan-selectin inhibitors alter the body's excessive inflammatory response."

Revotar's lead candidate Bimosiamose is the clinically most advanced pan-selectin antagonist in the world. Already, Bimosiamose has successfully passed several clinical phase I and phase IIa trials in asthma, COPD and psoriasis and has shown excellent safety and efficacy profiles in these trials. A further phase IIa study of Bimosiamose in COPD is scheduled to start in 2010.

According to the World Health Organization (WHO), COPD is a serious, under-diagnosed, life threatening inflammatory lung disease that may progressively lead to death. "There is currently no safe and effective anti-inflammatory drug available for the treatment of COPD," said Dr. Daniel Bock, Director Preclinical & Clinical R&D at Revotar. "Unlike asthma, the effect of corticosteroids in COPD is a matter of considerable debate."

About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises several serious conditions affecting the lung. According to the WHO, COPD is affecting more than 210 million people worldwide, of which about 80 million people suffer from moderate to severe forms of the disease. More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. The WHO predicts that COPD will become the third leading cause of death worldwide by 2030. In 2007, the global COPD market recorded sales of more than 5 billion US-\$, with the US, France, Germany, Italy, Spain, UK and Japan accounting for 4.3 billion US-\$.



About Revotar Biopharmaceuticals AG

Revotar develops innovative drugs for inflammatory indications such as psoriasis, asthma, chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI). Its lead candidate Bimosiamose, a pan-selectin antagonist, has already passed several clinical phase I and phase IIa trials in asthma, COPD and psoriasis with a good safety and efficacy profile in over 200 patients and volunteers. Furthermore, Revotar has two preclinical programs addressing respiratory and dermatological indications in its pipeline. In 2006, Revotar announced a Start-Up Development Agreement with a US pharma company for the further development of Bimosiamose in one major disease area. In 2007 and 2008, Revotar raised approximately 9 million Euro and has further commitments of 3 to 4 million Euro based on certain preconditions to be met.

Contact:

Dr Martin Pöhlchen, CEO
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a
D-16761 Hennigsdorf / Germany
Phone: +49-3302-2025010
Fax: +49-3302-2025030
Email: info@revotar-ag.de
www.revotar.de